Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

Share Price is delayed by 15 minutes
Get Live Data
13,290.00    56.00 (0.42%)
Bid:
13,338.00
Ask:
13,344.00
Spread: 6.00 (0.045%)
Market Cap: £206.11b
AZN Live PriceLast checked at - London Stock Exchange

Intraday Astrazeneca Share Chart

Astrazeneca News

US regulator greenlights AstraZeneca's blood pressure drug Baxfendy
18 May 2026

US regulator greenlights AstraZeneca's blood pressure drug Baxfendy

(Alliance News) - AstraZeneca PLC on Monday reported US clearance for its hypertension treatment Baxfendy.

AstraZeneca secures US approval for two drugs
18 May 2026

AstraZeneca secures US approval for two drugs

(Sharecast News) - Two AstraZeneca drugs have been given the green light in America to treat high blood pressure and breast cancer, the blue chip conf...

REFILE-FDA drug center head expected to leave after commissioner's exit, sources say
16 May 2026

REFILE-FDA drug center head expected to leave after commissioner's exit, sources say

* Hoeg's departure comes amid broader shakeup of ​health agency

CORRECT: AstraZeneca bladder cancer trial yields encouraging results
14 May 2026

CORRECT: AstraZeneca bladder cancer trial yields encouraging results

(Correction clarifies that the phase III Volga trial was conducted across three arms and provides the findings for arms 1 and 2 versus the comparator ...

AstraZeneca immunotherapy for stomach cancer green lit for NHS use
14 May 2026

AstraZeneca immunotherapy for stomach cancer green lit for NHS use

(Alliance News) - Patients with aggressive stomach cancer are to benefit from a new type of treatment after the NHS spending watchdog approved the fir...

AstraZeneca's bladder cancer drug yields encouraging test results
14 May 2026

AstraZeneca's bladder cancer drug yields encouraging test results

(Alliance News) - AstraZeneca PLC on Thursday posted positive trial results for its bladder cancer treatment imfinzi.

AstraZeneca hails phase-3 trial results for hypoparathyroidism drug
12 May 2026

AstraZeneca hails phase-3 trial results for hypoparathyroidism drug

(Alliance News) - AstraZeneca on Tuesday hailed encouraging test results for its hypoparathyroidism drug eneboparatide.

Novo Nordisk weight-loss pill powers profit beat in race to catch Eli Lilly
6 May 2026

Novo Nordisk weight-loss pill powers profit beat in race to catch Eli Lilly

* Novo nudges up full-year guidance ​after sales, profit beats